GURUFOCUS.COM » STOCK LIST » USA » NAS » Neuronetics Inc (NAS:STIM) » Definitions » ROE %
Switch to:

Neuronetics ROE %

: -57.49% (As of Jun. 2022)
View and export this data going back to 2018. Start your Free Trial

ROE % is calculated as Net Income attributable to Common Stockholders (Net Income minus dividends to participating security holders) divided by its average Total Stockholders Equity over a certain period of time. Neuronetics's annualized net income attributable to common stockholders for the quarter that ended in Jun. 2022 was $-41.69 Mil. Neuronetics's average Total Stockholders Equity over the quarter that ended in Jun. 2022 was $72.51 Mil. Therefore, Neuronetics's annualized ROE % for the quarter that ended in Jun. 2022 was -57.49%.

The historical rank and industry rank for Neuronetics's ROE % or its related term are showing as below:

STIM' s ROE % Range Over the Past 10 Years
Min: -74.86   Med: -56.37   Max: -44.27
Current: -44.27

During the past 6 years, Neuronetics's highest ROE % was -44.27%. The lowest was -74.86%. And the median was -56.37%.

STIM's ROE % is ranked worse than
79.65% of 226 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.13 vs STIM: -44.27

Neuronetics ROE % Historical Data

The historical data trend for Neuronetics's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuronetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROE %
Premium Member Only - - -48.86 -74.86 -56.37

Neuronetics Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.23 -34.64 -34.66 -53.60 -57.49

Competitive Comparison

For the Diagnostics & Research subindustry, Neuronetics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Neuronetics ROE % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Neuronetics's ROE % distribution charts can be found below:

* The bar in red indicates where Neuronetics's ROE % falls into.



Neuronetics ROE % Calculation

Neuronetics's annualized ROE % for the fiscal year that ended in Dec. 2021 is calculated as

ROE %=Net Income attributable to Common Stockholders (A: Dec. 2021 )/( (Total Stockholders Equity (A: Dec. 2020 )+Total Stockholders Equity (A: Dec. 2021 ))/ count )
=-31.193/( (25.493+85.175)/ 2 )
=-31.193/55.334
=-56.37 %

Neuronetics's annualized ROE % for the quarter that ended in Jun. 2022 is calculated as

ROE %=Net Income attributable to Common Stockholders (Q: Jun. 2022 )/( (Total Stockholders Equity (Q: Mar. 2022 )+Total Stockholders Equity (Q: Jun. 2022 ))/ count )
=-41.688/( (76.598+68.422)/ 2 )
=-41.688/72.51
=-57.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income attributable to common stockholders of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income attributable to common stockholders data used here is four times the quarterly (Jun. 2022) net income attributable to common stockholders data. ROE % is displayed in the 30-year financial page.


Neuronetics  (NAS:STIM) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %**(Q: Jun. 2022 )
=Net Income/Total Stockholders Equity
=-41.688/72.51
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-41.688 / 65.316)*(65.316 / 126.4485)*(126.4485 / 72.51)
=Net Margin %*Asset Turnover*Equity Multiplier
=-63.83 %*0.5165*1.7439
=ROA %*Equity Multiplier
=-32.97 %*1.7439
=-57.49 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %**(Q: Jun. 2022 )
=Net Income/Total Stockholders Equity
=-41.688/72.51
=(Net Income /Pre-Tax Income) * (Pre-Tax Income/Operating Income) * (Operating Income/Revenue) * (Revenue/Total Assets) * (Total Assets/Total Stockholders Equity)
= (-41.688 / -41.688) * (-41.688 / -39.184) * (-39.184 / 65.316) * (65.316 / 126.4485) * (126.4485 / 72.51)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.0639 * -59.99 % * 0.5165 * 1.7439
=-57.49 %

Note: The net income attributable to common stockholders data used here is four times the quarterly (Jun. 2022) net income attributable to common stockholders data. The Revenue data used here is four times the quarterly (Jun. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.


Be Aware

Net income attributable to common stockholders is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Neuronetics ROE % Related Terms

Thank you for viewing the detailed overview of Neuronetics's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuronetics Business Description

Neuronetics logo
Traded in Other Exchanges
Address
3222 Phoenixville Pike, Malvern, PA, USA, 19355
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Executives
Cannell Capital Llc 10 percent owner 245 MERIWETHER CIRCLE ALTA WY 83414
Rosengarten Megan director C/O NEURONETICS, INC. 3222 PHOENIXVILLE PIKE MALVERN PA 19355
Cascella Robert director C/O HOLOGIC, INC. BEDFORD MA 01730
Shook Bruce Joseph director 162 CRICKET AVE ARDMORE PA 19003
Jaeger Wilfred E director C/O THREE ARCH PARTNERS 3200 ALPINE RD PORTOLA VALLEY CA 94028
Bakewell John K director C/O LANTHEUS MEDICAL IMAGING, INC. 331 TREBLE COVE ROAD NO. BILLERICA MA 01862
Conley Sheryl L director C/O NEURONETICS, INC. 3222 PHOENIXVILLE PIKE MALVERN PA 19355
Muir Glenn P director C/O HOLOGIC, INC. BEDFORD MA 01730
Sullivan Keith J director, officer: President and CEO C/O RELIANT TECHNOLOGIES, INC. 464 ELLIS STREET MOUNTAIN VIEW CA 94043
Macan William Andrew officer: Sr. VP, GC, CCO and Secretary 24275 KATY FREEWAY, SUITE 600 KATY TX 77494
Harper Gregory officer: VP of Prod. Dev. & Operations C/O NEURONETICS, INC 3222 PHOENIXVILLE PIKE MALVERN PA 19355
Furlong Stephen officer: CFO C/O NEURONETICS, INC. 3222 PHOENIXVILLE PIKE MALVERN PA 19355
Tropsha Yelena officer: VP of Commercial Access C/O NEURONETICS, INC 3222 PHOENIXVILLE PIKE MALVERN PA 19355
Farley Brian E director 2200 ZANKER ROAD SUITE F SAN JOSE CA 95131
Guthrie Daniel officer: Chief Commercial Officer C/O NEURONETICS, INC 322 PHOENIXVILLE PIKE MALVERN PA 19355

Neuronetics Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)